Wide Ranks

AFMD

Affimed N.V.

2.84

Top Statistics
Market Cap 46 M Forward PE -1.08 Revenue Growth -90.00 %
Current Ratio 2.71 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.5240 Enterprise / Revenue 5.02 Price To Sales Trailing12 Months 6.27
Profitability
Profit Margins 0.00 % Operating Margins -7406.19 %
Balance Sheet
Total Cash 34 M Total Cash Per Share 2.20 Total Debt 14 M
Total Debt To Equity 50.55 Current Ratio 2.71 Book Value Per Share 3.85
All Measures
Short Ratio 1246.00 % Message Board Id finmb_849883 Fax 49 621 56003 649
Shares Short Prior Month 653612 Return On Equity -1.24 City Mannheim
Uuid a8ac0d1a-dfe3-38a8-9a5f-268608bb683d Previous Close 2.87 First Trade Date Epoch Utc 1 B
Book Value 3.85 Beta 2.10 Total Debt 14 M
Volume 155890 Price To Book 0.7369 Last Split Date 1 B
Fifty Two Week Low 2.61 Total Cash Per Share 2.20 Total Revenue 7 M
Shares Short Previous Month Date 1 B Target Median Price 23.63 Audit Risk 2
Max Age 86400 Recommendation Mean 1.50 Sand P52 Week Change 0.3133
Operating Margins -7406.19 % Target Mean Price 26.74 Net Income To Common -79186000
Short Percent Of Float 0.0666 Implied Shares Outstanding 16 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 211050 Average Volume10days 211050
Total Cash 34 M Next Fiscal Year End 1 B Revenue Per Share 0.4930
Held Percent Insiders 0.0601 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 3 Regular Market Previous Close 2.87
Target Low Price 9.48 Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.31
Open 2.87 Free Cashflow -52466876 Dividend Yield 0.00 %
Return On Assets -0.4931 Time Zone Short Name EST Board Risk 8
Trailing Eps -4.77 Day Low 2.71 Address1 Gottlieb-Daimler-Straße 2
Shares Outstanding 16 M Compensation Risk 9 Price Hint 4
Target High Price 55.12 Website https://www.affimed.com 52 Week Change -0.3689
Average Volume 109582 Forward Eps -2.61 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 240.90 % Last Split Factor 1:10
Regular Market Day High 2.92 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 50.55 Fifty Two Week High 8.95 Day High 2.92
Shares Short 982934 Regular Market Open 2.87 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 5.02 Revenue Growth -90.00 %
Shares Percent Shares Out 0.0627 Operating Cashflow -84022000 Currency USD
Time Zone Full Name America/New_York Market Cap 46 M Is_nasdaq_100 False
Zip 68165 Quote Type EQUITY Industry Biotechnology
Long Name Affimed N.V. Overall Risk 8 Regular Market Day Low 2.71
Held Percent Institutions 0.3699 Current Price 2.84 Enterprise To Ebitda -0.5240
Financial Currency EUR Current Ratio 2.71 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 7 Country Germany
Float Shares 13 M Two Hundred Day Average 4.72 Governance Epoch Date 1 B
Enterprise Value 37 M Price To Sales Trailing12 Months 6.27 Forward PE -1.08
Regular Market Volume 155890 Ebitda -71172000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Affimed N.

V.

, a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany.

The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.

It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.

It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd.

to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers.

The company was formerly known as Affimed Therapeutics B.

V.

and changed its name to Affimed N.

V.

in October 2014.

Affimed N.

V.

was founded in 2000 and is headquartered in Mannheim, Germany.